IRIS
FORMICA, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.655
AS - Asia 3.416
EU - Europa 2.414
SA - Sud America 535
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 6
Totale 27.073
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.536
SG - Singapore 1.516
CN - Cina 617
IT - Italia 567
BR - Brasile 457
RU - Federazione Russa 425
HK - Hong Kong 367
VN - Vietnam 280
DE - Germania 261
UA - Ucraina 237
BD - Bangladesh 219
IE - Irlanda 219
FR - Francia 156
JP - Giappone 123
GB - Regno Unito 116
FI - Finlandia 107
SE - Svezia 94
PL - Polonia 84
CA - Canada 62
KR - Corea 62
IN - India 57
NL - Olanda 42
ID - Indonesia 36
AR - Argentina 35
MX - Messico 31
IQ - Iraq 22
AT - Austria 21
ES - Italia 21
BE - Belgio 17
TR - Turchia 14
PK - Pakistan 13
EC - Ecuador 12
ZA - Sudafrica 12
SA - Arabia Saudita 10
AE - Emirati Arabi Uniti 8
EU - Europa 8
MY - Malesia 8
PH - Filippine 8
LT - Lituania 7
NP - Nepal 7
PY - Paraguay 7
TH - Thailandia 7
CL - Cile 6
CO - Colombia 6
CZ - Repubblica Ceca 6
AL - Albania 5
AU - Australia 5
CH - Svizzera 5
CR - Costa Rica 5
HN - Honduras 5
IL - Israele 5
JM - Giamaica 5
MA - Marocco 5
TN - Tunisia 5
BG - Bulgaria 4
EG - Egitto 4
KE - Kenya 4
KG - Kirghizistan 4
NI - Nicaragua 4
UY - Uruguay 4
UZ - Uzbekistan 4
JO - Giordania 3
LB - Libano 3
PE - Perù 3
QA - Qatar 3
RO - Romania 3
VE - Venezuela 3
AZ - Azerbaigian 2
BY - Bielorussia 2
ET - Etiopia 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
IR - Iran 2
KW - Kuwait 2
MN - Mongolia 2
MT - Malta 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PT - Portogallo 2
RS - Serbia 2
SI - Slovenia 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BM - Bermuda 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GF - Guiana Francese 1
GY - Guiana 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
Totale 27.067
Salva come PNG Salva come JPEG
Città #
Woodbridge 5.250
Wilmington 4.708
Houston 4.626
Singapore 814
Fairfield 573
San Jose 485
Ashburn 480
Hong Kong 361
Chandler 342
Ann Arbor 336
Seattle 263
Beijing 260
Cambridge 215
Jacksonville 213
Dublin 204
Council Bluffs 180
Rome 163
Medford 162
New York 160
Dallas 149
Santa Clara 138
The Dalles 119
Los Angeles 115
Tokyo 109
Ho Chi Minh City 91
Dearborn 89
Engelhard 85
Buffalo 72
Lawrence 72
Hanoi 68
Menlo Park 67
Kraków 64
Moscow 64
Milan 57
Lauterbourg 56
San Diego 46
Helsinki 41
Chicago 39
Saint Petersburg 35
Orem 34
Redondo Beach 33
São Paulo 33
Zhengzhou 33
Frankfurt am Main 25
Jakarta 25
Falls Church 24
Boardman 22
Chennai 19
Montreal 19
Mülheim 19
Nuremberg 19
London 18
Brussels 17
Brooklyn 16
Mexico City 16
North Bergen 16
Warsaw 16
Lappeenranta 15
Rio de Janeiro 14
Atlanta 13
Belo Horizonte 13
Cagliari 13
Porto Alegre 13
San Francisco 13
Turin 13
Detroit 12
Phoenix 12
Boston 11
Munich 11
Salt Lake City 11
Denver 10
Mumbai 10
Nanjing 10
Norwalk 10
Seoul 10
Shanghai 10
Stockholm 10
Toronto 10
Amsterdam 9
Bologna 9
Columbus 9
Haiphong 9
Hangzhou 9
Hefei 9
Redwood City 9
Vienna 9
Brasília 8
Curitiba 8
Kunming 8
Manchester 8
Palo Alto 8
Tampa 8
Vancouver 8
Charlotte 7
Johannesburg 7
Mannheim 7
Monte Vista 7
Naples 7
Salvador 7
Sorocaba 7
Totale 22.196
Salva come PNG Salva come JPEG
Nome #
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report 531
Preclinical studies on detection of circulating melanoma cells in patients: Telomerase as a recognition marker of malignancy 504
Drug-induced increase of carcinoembryonic antigen expression in cancer cells 490
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients 478
Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass 471
Effects of conventional therapeutic interventions on the number and function of regulatory T cells 465
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies 463
Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients 463
Biological and predictive role of ERCC1 polymorphisms in cancer 462
TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy 455
Prognostic value of glycated hemoglobin in colorectal cancer 454
Immune reaction and colorectal cancer: friends or foes? 453
Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio 452
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 450
Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer 446
Thromboembolic events in patients treated with anti-angiogenic drugs 442
Are there alternative ways to quantify the real benefit of novel agents in oncology? - The 'death pace' 435
Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience 429
Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression 429
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer 428
Family history of cancer in patients with gastric cancer 426
The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience 419
VEGF gene promoter polymorphisms and risk of VTE in chemotherapytreated cancer patients 417
Insulinemia and the risk of breast cancer and its relapse 416
CD26: a multi-purpose pharmacological target 412
Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle 410
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy 410
VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea 408
Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin 405
Up-regulation of carcinoembryonic antigen (CEA) expression by staurosporine in circulating colon cancer cells 404
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro 398
Targeted therapy in first line treatment of RAS wild type colorectal cancer 396
Kallikrein-related peptidases targeted therapies in prostate cancer: Perspectives and challenges 394
A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes 391
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients 390
Caregiver distress in the early phases of cancer 387
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B) 382
Prognostic significance of serum adipokine levels in colorectal cancer patients 381
Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches 380
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 374
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab 373
Non-steroidal anti-inflammatory drugs in cancer prevention and therapy 371
Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol 351
A novel K-ras mutation in colorectal cancer. A case report and literature review 348
Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome 347
Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer 346
Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy 343
Clinical significance of glycemic parameters on venous thromboembolism risk preDiction in gastrointestinal cancer 325
Chemotherapy in patients with hereditary angioedema 323
Case report of a patient with breast metastasis from gastric cancer treated with paclitaxel and ramucirumab plus regional hyperthermia 314
Cancer patients in the emergency department: A "nightmare" that might become a virtuous clinical pathway 306
Histotype influences emergency presentation and prognosis in colon cancer surgery 252
Relevance of computed tomography and magnetic resonance imaging for penile metastasis after prostatectomy: uncommon case report and brief review of the literature 236
Complete blood count might help to identify subjects with high probability of testing positive to SARS-CoV-2 215
A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel 183
Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors 176
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset 166
Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors 163
Clinical care pathway program versus open-access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer 161
Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt 148
Clinical utility of plasma KRAS, NRAS and BRAF mutational analysis with real time PCR in metastatic colorectal cancer patients -The importance of tissue/plasma discordant cases 135
Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events? 132
Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case-Control Study 126
KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis 125
Irinotecan or oxaliplatin: which is the first move for the mate? 122
Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care 114
Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy? 113
Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy 112
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 111
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis 106
The effects of association of topical polydatin improves the preemptive systemic treatment on EGFR inhibitors cutaneous adverse reactions 106
Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study 105
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ?BRAF BeCool? study 104
Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice? 103
HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling 102
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response 101
A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma 99
Untailored vs. Gender- and Body-Mass-Index-Tailored Skeletal Muscle Mass Index (SMI) to Assess Sarcopenia in Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) 97
Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview 96
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 93
Gender differences in cancer-associated venous thromboembolism 93
Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and age 89
Solitary metachronous gastric metastasis from pulmonary adenocarcinoma: Report of a case 88
Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation 88
MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review 88
Role of systemic inflammation and CD45RO+CD8+ cells in metastatic colorectal cancer = Ruolo dell’infiammazione e delle cellule CD45RO+CD8+ nei tumori colorettali metastatici 86
Concordance of blood-based and normal tissue-based dihydropyrimidine dehydrogenase (DPYD) genotyping 86
Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy [3] 81
Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer 80
Role of systemic inflammation and CD45RO+CD8+ cells in metastatic colorectal cancer = Ruolo dell’infiammazione e delle cellule CD45RO+CD8+ nei tumori colorettali metastatici 77
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: The CARACAS study 75
Circulating Hepcidin Levels Are an Independent Predictor of Survival in Microsatellite Stable Metastatic Colorectal Cancer Patient Candidates for Standard First-Line Treatment 73
Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial–Mesenchymal Transition and Correlates with Progression of the Disease 70
Adjuvant therapy for very young women with breast cancer: Response according to biologic and endocrine features 70
PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials 69
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 67
Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data 66
Issues and promises of bevacizumab in prostate cancer treatment 66
Obesity and common pathways of cancer and cardiovascular disease 63
Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer 61
Totale 26.385
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.069
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.069
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022855 32 81 38 48 44 70 75 65 67 86 49 200
2022/2023936 87 73 21 113 116 228 73 56 82 10 42 35
2023/2024567 40 16 36 20 33 103 176 51 7 4 5 76
2024/20252.499 56 488 207 125 33 182 165 160 443 254 203 183
2025/20264.996 367 278 630 387 406 192 496 583 530 403 437 287
2026/2027139 139 0 0 0 0 0 0 0 0 0 0 0
Totale 27.506